Recorded March 9, 2021 | On-Demand Webinar
Distinguish between human cellular and tissue-based products (HCT/P). Reviewthe regulatory framework for the regulation of regenerative medicine products and discuss key definitions and eligible therapies. Examine expedited programs for RMATs. Review emerging issues in gene editing, in-office procedures and stem cell manufacturing practices.
This session was recorded as part of FDLI’s virtual Introduction to Biologics and Biosimilars Law and Regulation course in March 2021.